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Treatment of locally advanced non-small cell lung cancerneoadjuvant or adjuvant chemotherapy
Vokes, Everett E. The University of Chicago, Chicago, IL, USA Over recent years combined modality therapy has become firmly established as a standard in the treatment of patients with locoregionally advanced unresectable non-small cell lung cancer (NSCLC). In direct comparison, concomitant chemoradiotherapy was shown repeatedly to be superior to induction chemotherapy. A case can be made that concomitant chemoradiotherapy primarily addresses locoregional disease while induction chemotherapy might be better suited to eradicate distant micrometastatic foci. Therefore, continuing sequential and concomitant therapy might be beneficial and the addition of induction or adjuvant chemotherapy to the concomitant chemoradiotherapy standard have been investigated. CALGB 39801 compared concomitant chemoradiotherapy using the carboplatin paclitaxel platform versus induction chemotherapy with carboplatin and paclitaxel for two cycles followed by identical chemoradiotherapy. While a numerical trend favored the induction chemotherapy arm, there was no significant advantage for overall survival. Similarly, the Hoosier Oncology Group evaluated the administration of concomitant chemoradiotherapy using the cisplatin etoposide platform with or without three additional cycles of consolidation chemotherapy with docetaxel. This study was based on promising pilot data generated by the Southwest Oncology Group. Again, the study showed no significant survival advantage from the addition of concomitant chemoradiotherapy. Therefore, at the present time, concomitant chemoradiotherapy should be regarded as the standard approach for most patients with unresectable non-small cell lung cancer. Induction chemotherapy may have a role for patients with poor performance status who may not be candidates to undergo aggressive chemoradiotherapy. Certain targeted agents might be appropriate to investigate in the consolidation setting under carefully defined experimental conditions. This need is highlighted by the recent experience in SWOG 0023 in which the administration of gefitinib as maintenance therapy was found to decrease survival rates. range. It is therefore advantageous to use light to detect pre-invasive lung caner and preneoplastic lesions that are usually very thin and small. When tissue is illuminated by light, the light can be absorbed, scattered, induce fluorescence or vibration changes. Significant differences in reflectance and autofluorescence properties have been observed between normal, pre-malignant and malignant tissues. These differences in optical properties have been exploited to enhance the detection rate of high-grade bronchial dysplasia and carcinoma in-situ. Current commercially available autofluorescence bronchoscopy devices make use of a combination of autofluorescence and reflectance. A blue or violet light is used to induce tissue autofluorescence. The fluorescence image is then combined with a blue, red and/or green reflectance image for display. In addition to multiple single center studies, there are 3 multi-center clinical trials and two randomized trials that showed improved detection rate with fluorescence bronchoscopy or with fluorescence-reflectance bronchoscopy compared to white-light bronchosocpy alone. Autofluorescence bronchoscopy has the advantage that a biopsy can be taken during the same examination for pathological confirmation. For cancer beyond the range of the bronchoscope, gene expression analysis of bronchial brush cells holds promise to differentiate between malignant versus benign peripheral lung nodules. Autofluorescence bronchoscopy has contributed to improved histopathological classification and molecular profiling of preneoplastic lesions. It has become an integral part of a standard bronchoscopic examination for lung cancer diagnosis. False-positive fluorescence can occur due to inflammation or conditions that increase vascularity of the bronchial mucosa. Optical coherence tomography (OCT) can overcome this problem by allowing visualization of the sup-epithelial layers. The principle of OCT is similar to ultrasound. Instead of using sound, infrared light is used. Back-scattered light from varying tissue depths can be used to delineate cellular and extra-cellular structures. Doppler OCT can add further information on vascular density and blood flow. Recent studies showed that high-grade dysplasia, carcinoma in-situ and invasive cancer can be distinguished from normal, hyperplastic or metaplastic epithelium. Interruption of the basement membrane would indicate the presence of invasive cancer. Areas of inflammation also show distinctive changes. Since small preneoplastic lesions can be removed by a biopsy procedure, OCT holds promise as a non-biopsy tool to study the natural history of preneoplastic lesions and the effect of chemoprevention.
Session E08: New Technology for Diagnosis
In the context of an early lung cancer detection program, approximately 18% of cancers -majority of which being Stage 0 caners, are detected by fluorescence bronchoscopy alone with a negative spiral CT. Lung cancer risk assessment models using biometric data such as family history, presence or absence of chronic obstructive pulmonary disease, family history of lung cancer and body mass index in addition to age, smoking history and occupational exposure are being validated. These models have the potential to predict the risk of lung cancer development better than the Gail model for breast cancer. Prospective clinical trials need to be performed to validate the use of these lung cancer risk models to select individuals at highest risk of developing lung cancer for intensive screening utilizing both fluorescence-reflectance bronchoscopy and spiral CT to detect early cancer in both the central and peripheral airways that are amendable to curative therapies. References For lymph node assessment in lung cancer patients, EBUS-TBNA can be used for preoperative evaluation as well as post-chemotherapy and post-operative evaluation. To evaluate the usefulness of CP-EBUS in pre-operative lymph node staging of lung cancer, we performed EBUS-TBNA in 108 patients with lung cancer or suspected lung cancer having mediastinal lymph nodes suspected of malignancy. In 105 patients, EBUS-TBNA was successfully performed to obtain samples from 163 lymph nodes. With respect to the correct prediction of lymph node stage, EBUS-TBNA had a sensitivity of 94.6%, specificity of 100%, positive predictive value of 100%, negative predictive value of 89.5%, and diagnostic accuracy rate of 96.3%. In the 20 suspected lung cancer cases, mediastinal lymph node was used for tissue diagnosis of malignancy as well as staging. As a result of EBUS-TBNA, 29 mediastinoscopies, 8 thoracotomies, 4 thoracoscopies, and 9 CT-guided PCNB were avoided 3 . In addition, a cost effectiveness study comparing EBUS-TBNA to other conventional tools used for mediastinal staging
